<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly!

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Head and Neck Cancer PDX Models

Head and neck cancers start in the organs of the head or neck such as mouth, throat, and lips. As with all cancer treatment development, a predictive preclinical model is needed for therapy evaluation. Patient-derived xenograft (PDX) models present a true representation of the human heterogeneity and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. Crown Bioscience has a large collection of head and neck cancer PDX models, including many with EGFR amplification. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL NUMBER CANCER TYPE CANCER SUBTYPE DESCRIPTION # per page
HN0366 Head and Neck Cancer HNSCC Squamous cell carcinoma of hypopharynx, Regional LN: LN from left redical neck dissection (2/5). CLICK TO VIEW
HN0586 Head and Neck Cancer HNSCC NA for clinical diagnosis info. Pathology QC: Moderately to poorly differentiated squamous cell carcinoma with massive necrosis (Pa, P6) CLICK TO VIEW
HN0626 Head and Neck Cancer HNSCC Squamous cell carcinoma. Regional LN: LN from left redical neck dissection (0/11). CLICK TO VIEW
HN0635 Head and Neck Cancer HNSCC Squamous cell carcinoma from left mandible, well-moderately differentiated, tumor mass: 11cm x 6cm x 4.5 cm, invading surrounding soft tissue. No malignant cells in mucous membrane of Regional LN: left mandibular LN: (1/2). CLICK TO VIEW
HN0696 Head and Neck Cancer HNSCC Squamous cell carcinoma of laryngeal. Regional LN: LN from left redical neck dissection (1/6), LN from right redical neck dissection (0/7). Leukoplakia with squamous cell atypical hyperplasia of left vocal chords. CLICK TO VIEW
HN1391 Head and Neck Cancer HNSCC Squamous cell carcinoma of left tongue, well differentiated, tumor mass: 3 x 3 x 0.8cm CLICK TO VIEW
HN1420 Head and Neck Cancer HNSCC Squamous cell carcinoma of laryngeal, moderately differentiated. CLICK TO VIEW
HN1774 Head and Neck Cancer NA NA CLICK TO VIEW
HN1972 Head and Neck Cancer HNSCC NA for clinical diagnosis info. Pathology QC: Squamous cell carcinoma CLICK TO VIEW
HN2167 Head and Neck Cancer HNSCC Squamous cell carcinoma of larynx. Regional LN: LN from right redical neck dissection (0/7), LN from left redical neck dissection (0/9). CLICK TO VIEW
HN2170 Head and Neck Cancer HNSCC Squamous cell carcinoma of larynx. Regional LN: LN from right redical neck dissection (1/13), LN from left redical neck dissection (0/17). CLICK TO VIEW
HN2174 Head and Neck Cancer HNSCC N/A CLICK TO VIEW
HN2195 Head and Neck Cancer HNSCC Poorly differentiated squamous carcinoma with neuroendocrine carcinoma differentiation of hypopharynx. IHC results: CK(+), Vim(-), P63(+), Syn(-), SMA(-), Chr-A(-), CD56(+), NSE(+), Mart-1(-), HMB45(-). Regional LN: LN from left redical neck dissection (2/13). CLICK TO VIEW
HN2221 Head and Neck Cancer HNSCC Squamous cell carcinoma of larynx, tumor mass: 3cm x 3cm x 1cm. CLICK TO VIEW
HN2222 Head and Neck Cancer HNSCC Squamous cell carcinoma of larynx, tumor mass: 5cm x 8.5cm x 4.5cm. Regional LN: LN from left redical neck dissection (0/8), LN from right redical neck dissection (0/9). CLICK TO VIEW
HN2400 Head and Neck Cancer N/A N/A CLICK TO VIEW
HN2447 Head and Neck Cancer SCC NA CLICK TO VIEW
HN2448 Head and Neck Cancer HNSCC Tongue: squamous cell carcinoma CLICK TO VIEW
HN2574 Head and Neck Cancer SCC SCCA KERATINIZING CLICK TO VIEW
HN2575 Head and Neck Cancer SCC SCCA CLICK TO VIEW
HN2576 Head and Neck Cancer HNSCC SCCA NON KERATINIZING, HPV-, P16+ CLICK TO VIEW
HN2577 Head and Neck Cancer SCC SCCA KERATINIZING CLICK TO VIEW
HN2579 Head and Neck Cancer SCC SCCA CLICK TO VIEW
HN2581 Head and Neck Cancer SCC SCCA CLICK TO VIEW
HN2583 Head and Neck Cancer SCC SPINDLE CELL SCCA CLICK TO VIEW
HN2586 Head and Neck Cancer SCC SCCA KERATINIZING CLICK TO VIEW
HN2588 Head and Neck Cancer HNSCC SCCA CLICK TO VIEW
HN2590 Head and Neck Cancer HNSCC SCCA KERATINIZING CLICK TO VIEW
HN2593 Head and Neck Cancer NA SCCA KERATINIZING CLICK TO VIEW
HN2594 Head and Neck Cancer HNSCC SCCA SARCOMATOID CLICK TO VIEW
HN2603 Head and Neck Cancer SCC SCCA KERATINIZING CLICK TO VIEW
HN2606 Head and Neck Cancer HNSCC SCCA KERATINIZING CLICK TO VIEW
HN2609 Head and Neck Cancer HNSCC SCCA KERATINIZING CLICK TO VIEW
HN2615 Head and Neck Cancer HNSCC SCCA CLICK TO VIEW
HN2616 Head and Neck Cancer HNSCC NA CLICK TO VIEW
HN2621 Head and Neck Cancer HNSCC SCCA NONKERATINIZING CLICK TO VIEW
HN2622 Head and Neck Cancer SCC SPINDLE CELL SCCA CLICK TO VIEW
HN2626 Head and Neck Cancer HNSCC NA CLICK TO VIEW
HN3067 Head and Neck Cancer HNSCC Squamous cell carcinoma of right cavum laryngis, grade I-II. CLICK TO VIEW
HN3164 Head and Neck Cancer ADC Right parotid gland: ductal adenocarcinoma CLICK TO VIEW
HN3186 Head and Neck Cancer SCC Tongue: moderately differentiated squamous cell carcinoma CLICK TO VIEW
HN3293 Head and Neck Cancer HNSCC Right tempus: moderately differentiated squamous cell carcinoma CLICK TO VIEW
HN3388 Head and Neck Cancer NA Right cheek: squamous epithelial papilloma cancerization CLICK TO VIEW
HN3411 Head and Neck Cancer HNSCC Larynx: well differentiated squamous cell carcinoma, lymph node is benign (0/1) CLICK TO VIEW
HN3412 Head and Neck Cancer HNSCC left neck: poorly differentiated squamous cell carcinoma, consider metastatic squamous cell carcinoma to lymph nodes CLICK TO VIEW
HN3456 Head and Neck Cancer HNSCC Right frontal part: moderately differentiated squamous cell carcinoma. CLICK TO VIEW
HN3461 Head and Neck Cancer HNSCC Left tongue: well differentiated squamous cell carcinoma CLICK TO VIEW
HN3472 Head and Neck Cancer SCC NA CLICK TO VIEW
HN3474 Head and Neck Cancer HNSCC Scalp: well differentiated squamous cell carcinoma CLICK TO VIEW
HN3502 Head and Neck Cancer NA NA CLICK TO VIEW
HN3504 Head and Neck Cancer HNSCC Well differentiated squamous cell carcinoma. CLICK TO VIEW
HN3508 Head and Neck Cancer HNSCC Left tongue: moderately differentiated squamous cell carcinoma CLICK TO VIEW
HN3513 Head and Neck Cancer HNSCC Floor of mouth: moderately differentiated squamous cell carcinoma with metastasis to right jaw. CLICK TO VIEW
HN3530 Head and Neck Cancer HNSCC Right pars oralis pharyngis: moderately to poorly differentiated squamous cell carcinoma. One out of one lymph node showed metastatic squamous cell carcinoma (1/1). CLICK TO VIEW
HN3533 Head and Neck Cancer Sarcomatoid Right mandibular gingiva: Sarcomatoid carcinoma. Two out of seventeen lymph nodes showed metastatic carcinoma (2/17). CLICK TO VIEW
HN3536 Head and Neck Cancer HNSCC Right maxillary sinus: moderately differentiated squamous cell carcinoma CLICK TO VIEW
HN3537 Head and Neck Cancer HNSCC Right nasal cavity and paranasal sinus: moderately differentiated squamous cell carcinoma. The tumor invaded into local bone tissue. CLICK TO VIEW
HN3540 Head and Neck Cancer HNSCC Hypopharynx: well differentiated squamous cell carcinoma. CLICK TO VIEW
HN3581 Head and Neck Cancer HNSCC Right salivary gland: well to moderately differentiated squamous cell carcinoma. All lymph nodes are benign (0/4). CLICK TO VIEW
HN3588 Head and Neck Cancer HNSCC Left face: moderately differentiated squamous cell carcinoma. CLICK TO VIEW
HN3599 Head and Neck Cancer HNSCC Total laryngectomy specimen: moderately differentiated squamous cell carcinoma. CLICK TO VIEW
HN3623 Head and Neck Cancer SCC NA CLICK TO VIEW
HN3629 Head and Neck Cancer NA Cervical lymph nodes: metastatic laryngeal carcinoma CLICK TO VIEW
HN3635 Head and Neck Cancer HNSCC Right tempora: well differentiated squamous cell carcinoma of skin CLICK TO VIEW
HN3642 Head and Neck Cancer HNSCC Right frontal part skin: well differentiated squamous cell carcinoma, infiltrating to skin dermis CLICK TO VIEW
HN3674 Head and Neck Cancer HNSCC Larynx: moderately differentiated squamous cell carcinoma. CLICK TO VIEW
HN3679 Head and Neck Cancer HNSCC Left cheek: moderately to poorly differentiated squamous cell carcinoma. Eleven of forty-nine lymph nodes involved by malignant carcinoma (11/49). CLICK TO VIEW
HN3690 Head and Neck Cancer HNSCC Larynx: moderately differentiated squamous cell carcinoma. CLICK TO VIEW
HN3697 Head and Neck Cancer HNSCC Palate: moderately differentiated squamous cell carcinoma CLICK TO VIEW
HN3712 Head and Neck Cancer HNSCC Right tongue: moderately to poorly differentiated squamous cell carcinoma. All lymph nodes are benign (0/19) CLICK TO VIEW
HN3721 Head and Neck Cancer N/A N/A CLICK TO VIEW
HN3776 Head and Neck Cancer HNSCC Left lower gingiva: moderately differentiated squamous cell carcinoma. CLICK TO VIEW
HN3792 Head and Neck Cancer HNSCC Left parotid gland: squamous cell carcinoma, moderately to poorly differentiated. CLICK TO VIEW
HN3796 Head and Neck Cancer HNSCC Gingiva of left underjaw: moderately differentiated squamous cell carcinoma, all lymph nodes are benign (0/44). CLICK TO VIEW
HN5111 Head and Neck Cancer HNSCC squamous cell head & neck. Pathol comment: c/w referring diagnosis. approximately 30% of the tissue involved by tumor in sections examined. tumor cells present in cytospin prep. CLICK TO VIEW
HN5116 Head and Neck Cancer HNSCC squamous cell head & necksquamous cell carcinoma. Pathol comment: c/w referring diagnosis. microscopic focus of malignant tumor present in sections examined. malignant tumor cells present in cytospin prep. CLICK TO VIEW
HN5123 Head and Neck Cancer HNSCC squamous carcinoma of h&n squamous cell carcinoma. Pathol comment: approximately 60% of the tissue involved by invasive malignant tumor in sections examined. 40% necrosis. c/w squamous cell carcinoma. approximately 30% malignant tumor cells present in cytospin preparation. CLICK TO VIEW
HN5124 Head and Neck Cancer HNSCC squamous carcinoma of h&n. Pathol comment: c/w diagnosis. approximately 90% of the tissue involved by malignant tumor in sections examined. 30% necrosis. approximately 10% malignant tumor cells present in cytospin preparation. CLICK TO VIEW
HN5125 Head and Neck Cancer HNSCC squamous carcinoma of h&nmetastatic poorly differentiated squamous carcinoma. Approximately 70% of the tissue involved by malignant tumor in sections examined. focal tumor necrosis. c/w squamous cell carcinoma. approximately 30% malignant tumor cells present in cytospin preparation. CLICK TO VIEW
HN9280 Head and Neck Cancer HNSCC NA CLICK TO VIEW
HN9287 Head and Neck Cancer HNSCC NA CLICK TO VIEW
HN9298 Head and Neck Cancer Adenocarcinoma NA CLICK TO VIEW
HN9299 Head and Neck Cancer Adenocarcinoma NA CLICK TO VIEW

Sorry, no posts matched your criteria.

Create Account to View All Model Data

Already Registered? Login